tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

GSK completes acquisition of efimosfermin alfa from Boston Pharmaceuticals
The FlyGSK completes acquisition of efimosfermin alfa from Boston Pharmaceuticals
14h ago
GSK
NVS
Novartis’ RED4MS Trial: A New Hope for Multiple Sclerosis Treatment?
PremiumCompany Announcements
Novartis’ RED4MS Trial: A New Hope for Multiple Sclerosis Treatment?
5d ago
NVS
Novartis reports GCAptAIN study did not meet primary endpoint
PremiumThe Fly
Novartis reports GCAptAIN study did not meet primary endpoint
5d ago
NVS
Novartis: Strong Growth and Product Performance Amid Valuation Concerns and Generic Competition Risks
PremiumRatings
Novartis: Strong Growth and Product Performance Amid Valuation Concerns and Generic Competition Risks
7d ago
NVS
Novartis completes acquisition of Regulus Therapeutics
PremiumThe Fly
Novartis completes acquisition of Regulus Therapeutics
13d ago
NVS
RGLS
Novartis announces expiration of Regulus Therapeutics tender offer
PremiumThe FlyNovartis announces expiration of Regulus Therapeutics tender offer
13d ago
NVS
RGLS
Novartis announces expiration of HSR waiting period of Regulus offer
Premium
The Fly
Novartis announces expiration of HSR waiting period of Regulus offer
15d ago
NVS
RGLS
Trump administration weighs crackdown on pharma ads, Bloomberg says
Premium
The Fly
Trump administration weighs crackdown on pharma ads, Bloomberg says
21d ago
AZN
BMY
Senators to propose ban on drug ads to consumers, WSJ reports
PremiumThe Fly
Senators to propose ban on drug ads to consumers, WSJ reports
26d ago
AZN
BMY
Novartis announces results from APPULSE-PNH study of Fabhalta
PremiumThe Fly
Novartis announces results from APPULSE-PNH study of Fabhalta
26d ago
NVS
RFK Jr. names eight members to vaccine panel, WSJ reports
PremiumThe Fly
RFK Jr. names eight members to vaccine panel, WSJ reports
26d ago
AZN
BMY
RFK Jr. names new CDC vaccine advisory panel picks, STAT reports
PremiumThe Fly
RFK Jr. names new CDC vaccine advisory panel picks, STAT reports
26d ago
AZN
BMY
Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel
PremiumThe FlyTrump Trade: RFK Jr. removes members of vaccine-advising CDC panel
28d ago
AZN
BMY
RFK Jr. reconstituting vaccine advisory committee, retiring 17 current members
Premium
The Fly
RFK Jr. reconstituting vaccine advisory committee, retiring 17 current members
28d ago
AZN
BMY
RFK Jr. removes members of vaccine-advising CDC panel, CNBC reports
Premium
The Fly
RFK Jr. removes members of vaccine-advising CDC panel, CNBC reports
28d ago
AZN
BMY
Vaccine opponent hired by RFK Jr. searches CDC record for autism link, WSJ says
PremiumThe Fly
Vaccine opponent hired by RFK Jr. searches CDC record for autism link, WSJ says
1M ago
AZN
BMY
Rapt Therapeutics started at Buy at Clear Street on RPT904b opportunity
PremiumThe Fly
Rapt Therapeutics started at Buy at Clear Street on RPT904b opportunity
1M ago
NVS
CHRO
Novartis announces Phase III PSMAddition trial met primary endpoint
PremiumThe Fly
Novartis announces Phase III PSMAddition trial met primary endpoint
1M ago
NVS
Cautious Outlook on Novartis AG Amid Promising Pluvicto Trial Results and Market Uncertainties
PremiumRatings
Cautious Outlook on Novartis AG Amid Promising Pluvicto Trial Results and Market Uncertainties
1M ago
NVS
Novartis AG: Hold Rating Amid Promising Trials and Competitive Challenges
PremiumRatingsNovartis AG: Hold Rating Amid Promising Trials and Competitive Challenges
1M ago
NVS
Novartis announces data from new subgroup analysis of Phase III NATALEE trial
Premium
The Fly
Novartis announces data from new subgroup analysis of Phase III NATALEE trial
1M ago
NVS
FTC renews Orange Book listing disputes
Premium
The Fly
FTC renews Orange Book listing disputes
2M ago
NVS
AMPH

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >